Indivior (NASDAQ:INDV) Given New $13.00 Price Target at Piper Sandler

Indivior (NASDAQ:INDV) had its price target dropped by equities research analysts at Piper Sandler from $16.00 to $13.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler’s price target would indicate a potential upside of 29.87% from the company’s current price.

A number of other equities analysts have also commented on the company. Rodman & Renshaw started coverage on Indivior in a research note on Tuesday, January 28th. They issued a “buy” rating and a $16.00 price objective on the stock. RODMAN&RENSHAW raised Indivior to a “strong-buy” rating in a research note on Tuesday, January 28th.

Indivior Price Performance

Shares of INDV stock opened at $10.01 on Thursday. The stock’s fifty day simple moving average is $11.02 and its 200 day simple moving average is $10.63. The firm has a market cap of $1.38 billion, a price-to-earnings ratio of -28.60 and a beta of 0.73. Indivior has a one year low of $7.33 and a one year high of $22.53.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Thursday, February 20th. The company reported $0.32 EPS for the quarter, hitting analysts’ consensus estimates of $0.32. The company had revenue of $298.00 million for the quarter, compared to analyst estimates of $262.35 million. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. On average, research analysts anticipate that Indivior will post 1.22 earnings per share for the current year.

Institutional Investors Weigh In On Indivior

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Rathbones Group PLC raised its position in shares of Indivior by 11.6% during the fourth quarter. Rathbones Group PLC now owns 14,284 shares of the company’s stock worth $183,000 after acquiring an additional 1,483 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Indivior by 4.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 41,327 shares of the company’s stock valued at $408,000 after purchasing an additional 1,888 shares during the last quarter. Two Sigma Investments LP increased its holdings in Indivior by 2.1% in the fourth quarter. Two Sigma Investments LP now owns 110,880 shares of the company’s stock valued at $1,378,000 after purchasing an additional 2,237 shares during the last quarter. Stifel Financial Corp increased its holdings in Indivior by 24.0% in the fourth quarter. Stifel Financial Corp now owns 12,675 shares of the company’s stock valued at $158,000 after purchasing an additional 2,450 shares during the last quarter. Finally, PDT Partners LLC increased its holdings in Indivior by 4.7% in the fourth quarter. PDT Partners LLC now owns 57,520 shares of the company’s stock valued at $715,000 after purchasing an additional 2,596 shares during the last quarter. Institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.